6-Keto-Prostaglandin E1and Bartter's Syndrome

Abstract

To the Editor: A consistent finding in patients with Bartter's syndrome is a reduction in the ex vivo responsiveness of their platelets to such aggregating agents as adenosine diphosphate (ADP), epinephrine, thrombin, and collagen.^{1 2 3} This platelet defect is probably due to a circulating plasma factor, since the defect can be readily conferred on normal platelets by suspending them in plasma obtained from a subject with Bartter's syndrome.^{1 2 3} That this factor is a prostacyclin-like compound is suggested by the observations that the platelet defect can be alleviated both by inhibition of prostaglandin synthesis^{1 2 3} and by antibodies against prostacyclin.³ However, unlike prostacyclin, . . .